Latest News
FDA approves BeOne's sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantel cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor
Details >Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
